Pfizer's China Strategy: Licensing Cancer Drug and Bi-Specific Antibody Technology

Pfizer's Strategic Deal with 3SBio

• 💡 Pfizer is entering a new China strategy by striking a deal with 3SBio, a Chinese company.
• 🤝 The agreement is to license a cancer drug that utilizes bi-specific antibody technology.

The Cancer Drug and Its Technology

• 🎯 The bi-specific antibody targets PD1 and VEGF, similar to the blockbuster drug Keytruda.
• 🔬 The licensed drug is already in clinical trials in China for various cancers, including non-small cell lung cancer, colorectal cancer, and gynecological tumors.
• 📈 3SBio plans to initiate a Phase 3 trial in China this year for the drug.

Financials and Market Trends

• 💰 Pfizer is paying $1.25 billion upfront and up to $4.8 billion for the rights to develop and sell the drug outside China.
• 📊 This deal is significant, costing roughly double what Merck paid for a similar licensing deal, highlighting interest in this technology and Chinese partnerships.
• 🇨🇳 A notable trend is that 42% of big pharma deals with at least $50 million upfront this year have come from China, surpassing last year's record.

Geopolitical Considerations and Clinical Trials

• ⚠️ While geopolitical tensions exist, deals continue to emerge, with Pfizer specifically stating plans to manufacture the drug in the US.
• 🇨🇳 China leads in drug development studies, with companies increasingly choosing it for trials due to faster progression and lower costs.
• 🚀 The speed and validated data at a lower cost in China are key drivers for companies, supported by China's concerted investment in biopharma.